Physician profile
Sandy Lee
NPI 1013404912
$5,827.44
in general payments reported to CMS, 2019-2025
25 companies · $766 in 2025
The $766 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $598 · 2023: $2,700 · 2024: $1,642 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906 · Honoraria: $1,193 · Travel and Lodging: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.00 |
| Honoraria | $1,193.00 |
| Travel and Lodging | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,572.28 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $1,015.79 | 2022-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $918.04 | 2021-2025 | Lupkynis |
| Janssen Biotech, INC. | $447.48 | 2023-2025 | Tremfya, Remicade, Simponi Aria |
| Abbvie INC. | $350.70 | 2023-2025 | |
| Amgen INC. | $336.59 | 2023-2025 | Enbrel, Krystexxa, Tavneos |
| Ucb, INC. | $314.11 | 2023-2025 | Cimzia, Bimzelx |
| Alexion Pharmaceuticals, INC. | $253.99 | 2023-2024 | Strensiq |
| Fresenius Kabi USA, LLC | $83.62 | 2024-2025 | Idacio |
| Radius Health, INC. | $74.45 | 2023-2024 | Tymlos |
| Ani Pharmaceuticals, INC. | $68.06 | 2024 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals Lp | $57.44 | 2024 | Saphnelo |
| Organon LLC | $42.44 | 2024 | |
| Novartis Pharmaceuticals Corporation | $38.97 | 2025 | |
| Bioventus LLC | $38.94 | 2024 | Durolane, Supartz Fx Sodium Hyaluronate |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $33.20 | 2023 | Acthar |
| Sandoz INC. | $27.37 | 2024 | Hyrimoz |
| Biocon Biologics INC | $26.27 | 2024 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.98 | 2024 | Cyltezo |
| Zimmer Biomet Holdings, INC. | $23.61 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Pfizer INC. | $20.03 | 2024 | |
| Genentech USA, INC. | $16.94 | 2023 | Actemra |
| Alvogen INC | $14.41 | 2024 | Teriparatide |
| Scilex Pharmaceuticals INC. | $14.01 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.72 | 2024 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.